DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site, 2021 Q3 to 2026 Q2
- $524M
- 88 holdings
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
AUM over time
Book
| XBI, SPDR S&P Biotech ETF | Add +2.7% | 415,505 | $82.93 | $34M | +11,000 | +$1.7M | |
| STXS, Stereotaxis | Hold | 13,680,554 | $2.12 | $29M | — | — | |
| RVMD, Revolution Medicines | Add +3.2% | 677,176 | $36.79 | $25M | +21,000 | +$1.7M | |
| Blueprint Medicines | Add +10.8% | 168,763 | $128.18 | $22M | +16,500 | +$8.2M | |
| Merus BV | Reduce −13.6% | 398,804 | $52.60 | $21M | −63,000 | +$1.5M | |
| ATRC, Atricure | Hold | 592,273 | $32.77 | $19M | — | — | |
| CYTK, Cytokinetics | Hold | 398,100 | $33.04 | $13M | — | — | |
| IDYA, Ideaya Biosciences | Add +5.0% | 619,090 | $21.02 | $13M | +29,760 | +$3.4M | |
| NDAQ, iShares Nasdaq Biotech Indx | Hold | 102,500 | $126.51 | $13M | — | — | |
| ASND, Ascendis Pharma A/s | Reduce −9.6% | 72,677 | $172.60 | $13M | −7,721 | +$13K | |
| XENE, Xenon Pharmaceuticals | Add +5.2% | 287,939 | $31.30 | $9M | +14,200 | −$171K | |
| NBIX, Neurocrine Biosciences | Reduce −1.4% | 70,615 | $125.69 | $8.9M | −1,000 | +$955K | |
| AXGN, Axogen | Add +9.0% | 741,782 | $10.85 | $8M | +61,000 | −$4.5M | |
| Kalvista Pharmaceuticals | Reduce −22.7% | 581,757 | $11.31 | $6.6M | −170,602 | −$2.1M | |
| DXCM, DexCom | Hold | 65,552 | $87.29 | $5.7M | — | — | |
| DAWN | Add +20.2% | 879,163 | $6.50 | $5.7M | +147,800 | −$85K | |
| STOK, Stoke Therapeutics | Add +13.1% | 501,972 | $11.35 | $5.7M | +57,974 | +$2.7M | |
| TNDM, Tandem Diabetes Care | Hold | 294,208 | $18.64 | $5.5M | — | — | |
| RCUS, Arcus Biosciences | Add +0.4% | 627,626 | $8.14 | $5.1M | +2,500 | +$202K | |
| SNDX, Syndax Pharmaceuticals | Reduce −0.2% | 543,602 | $9.37 | $5.1M | −900 | −$1.6M | |
| MLYS, Mineralys Therapeutics | Add +20.2% | 371,523 | $13.53 | $5M | +62,323 | +$117K | |
| URGN, Urogen | Reduce −29.0% | 349,515 | $13.70 | $4.8M | −143,000 | −$659K | |
| INGN, Inogen | Add +32.2% | 605,625 | $7.03 | $4.3M | +147,560 | +$992K | |
| LKFT, Galapagos | Hold | 130,175 | $27.99 | $3.6M | — | — | |
| BHVN, Biohaven | Add +6.8% | 235,235 | $14.11 | $3.3M | +15,000 | −$2M | |
| PRQR, Proqr Therapeutics | Hold | 1,567,561 | $2.04 | $3.2M | — | — | |
| EWTX, Edgewise Therapeutics | Add +30.0% | 238,140 | $13.11 | $3.1M | +55,000 | −$907K | |
| PODD, Insulet | Reduce −16.8% | 9,900 | $314.18 | $3.1M | −2,000 | −$15K | |
| IMVT, Immunovant | Add +12.6% | 191,493 | $16.00 | $3.1M | +21,497 | +$159K | |
| ALKS, Alkermes | Add +10.1% | 103,748 | $28.61 | $3M | +9,548 | −$142K | |
| BCAX, Bicara Therapeutics | Add +49.5% | 317,001 | $9.29 | $2.9M | +105,000 | +$183K | |
| TELA, Tela Bio | Hold | 1,441,029 | $1.94 | $2.8M | — | — | |
| KURA, Kura Oncology | Hold | 463,368 | $5.77 | $2.7M | — | — | |
| DNLI, Denali Therapeutics | Add +31.7% | 168,500 | $13.99 | $2.4M | +40,600 | +$619K | |
| CMPS, Compass Pathways | Add +14.1% | 811,046 | $2.80 | $2.3M | +100,000 | +$237K | |
| ALGN, Align Technology | Hold | 11,000 | $189.33 | $2.1M | — | — | |
| BCRX, Biocryst Pharmaceuticals | Reduce −60.9% | 218,255 | $8.96 | $2M | −340,000 | −$2.2M | |
| ATXS, Astria Therapeutics | Add +3.2% | 324,775 | $5.36 | $1.7M | +10,000 | +$60K | |
| Keros Therapeutics | Hold | 130,316 | $13.35 | $1.7M | — | — | |
| VKTX, Viking Therapeutics | Hold | 64,516 | $26.50 | $1.7M | — | — | |
| ARAY, Accuray | Hold | 1,222,358 | $1.37 | $1.7M | — | — | |
| BWAY, Brainsway | Reduce −18.8% | 127,151 | $13.15 | $1.7M | −29,382 | +$190K | |
| ALLO, Allogene Therapeutics | Hold | 1,380,118 | $1.13 | $1.6M | — | — | |
| LXEO, Lexeo Therapeutics | Hold | 378,083 | $4.02 | $1.5M | — | — | |
| FHTX, Foghorn Therapeutics | Reduce −1.4% | 300,452 | $4.70 | $1.4M | −4,300 | +$300K | |
| Iteos Therapeutics | Reduce −34.0% | 140,847 | $9.97 | $1.4M | −72,500 | +$131K | |
| ORIC, Oric Pharmaceuticals | Reduce −44.1% | 135,271 | $10.15 | $1.4M | −106,729 | +$23K | |
| CMPX, Compass Therapeutics | New | 526,660 | $2.60 | $1.4M | +526,660 | +$1.4M | |
| Immatics | Hold | 245,000 | $5.38 | $1.3M | — | — | |
| ALEC, Alector | Hold | 912,928 | $1.40 | $1.3M | — | — | |
| Mediwound | Hold | 64,479 | $19.37 | $1.2M | — | — | |
| GPCR, Structure Therapeutics | Hold | 59,000 | $20.74 | $1.2M | — | — | |
| BDTX | Add +236.4% | 471,000 | $2.48 | $1.2M | +331,000 | +$951K | |
| LRMR, Larimar Therapeutics | Hold | 371,434 | $2.89 | $1.1M | — | — | |
| Vyne Therapeutics | Hold | 636,103 | $1.65 | $1M | — | — | |
| Gossamer Bio | Reduce −6.4% | 849,921 | $1.23 | $1M | −57,933 | +$47K | |
| PVLA, Palvella Therapeutics | Hold | 43,348 | $22.54 | $977K | — | — | |
| AUTL, Autolus Therapeutics | Reduce −27.5% | 425,616 | $2.28 | $970K | −161,051 | +$61K | |
| IPSC, Century Therapeutics | Hold | 1,704,232 | $0.5587 | $952K | — | — | |
| NGNE, Neurogene | Reduce −0.8% | 51,096 | $14.95 | $764K | −404 | +$161K | |
| BNTX, Biontech | Reduce −33.3% | 7,000 | $106.47 | $745K | −3,500 | −$211K | |
| Polypid | Reduce −28.6% | 207,900 | $3.53 | $734K | −83,373 | −$55K | |
| Korro Bio | Add +22.5% | 57,691 | $12.49 | $721K | +10,605 | −$99K | |
| Compugen | Hold | 272,402 | $1.78 | $485K | — | — | |
| AQST, Aquestive Therapeutics | Hold | 142,000 | $3.31 | $470K | — | — | |
| BCYC, Bicycle Therapeutics | Reduce −20.2% | 64,492 | $6.95 | $448K | −16,307 | −$238K | |
| ERAS, Erasca | Add +2.9% | 350,000 | $1.27 | $445K | +10,000 | −$21K | |
| Adicet Bio | Reduce −10.0% | 540,000 | $0.6100 | $329K | −60,000 | −$124K | |
| ADCT, Adc Therapeutics | Reduce −45.5% | 122,081 | $2.68 | $327K | −102,000 | +$11K | |
| Sutro Biopharma | Hold | 437,079 | $0.7139 | $312K | — | — | |
| NKTR, Nektar Therapeutics | New | 10,000 | $25.84 | $258K | +10,000 | +$258K | |
| APRE, Aprea Therapeutics | Hold | 137,174 | $1.69 | $232K | — | — | |
| Biomx | Hold | 401,136 | $0.4500 | $181K | — | — | |
| PRCT, Procept Biorobotics | New | 3,000 | $57.60 | $173K | +3,000 | +$173K | |
| IFRX, Inflarx | Reduce −55.6% | 200,000 | $0.7900 | $158K | −250,000 | −$301K |
Showing top 50 of 75 by value
Exits / last held
Gone since 2025 Q1, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| 2seventy Bio | Exit | 0 | $4.94 | $2.1M | −429,252 | −$2.1M | |
| Regulus Therapeutics | Exit | 0 | $1.75 | $1.5M | −847,176 | −$1.5M | |
| SPRY, Ars Pharmaceuticals | Exit | 0 | $12.58 | $1.2M | −95,290 | −$1.2M | |
| Holding | Exit | 0 | $0.4515 | $1.1M | −2,511,374 | −$1.1M | |
| Sage Therapeutics | Exit | 0 | $7.95 | $860K | −108,200 | −$860K | |
| TSHA, Taysha Gene Therapies | Exit | 0 | $1.39 | $726K | −522,500 | −$726K | |
| CRDF, Cardiff Oncology | Exit | 0 | $3.14 | $471K | −150,000 | −$471K | |
| Nevro | Exit | 0 | $5.84 | $222K | −38,000 | −$222K | |
| Spero Therapeutics | Exit | 0 | $0.7200 | $90K | −125,000 | −$90K | |
| Tenaya Therapeutics | Exit | 0 | $0.5706 | $27K | −47,319 | −$27K |
Filings history
20 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site, 2021 Q3 to 2026 Q2